GXYLT1 Knockout HT29 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human HT29 colorectal adenocarcinoma cell line. This product comprises a heterogeneous pool of cells harboring disruptive mutations in the GXYLT1 gene, providing a robust loss-of-function model for investigating gene function without the confounding effects of clonal selection. The polyclonal format ensures comprehensive gene disruption across the culture while maintaining genetic diversity, making it well-suited for pooled functional screens and bulk biochemical analyses.
The parental HT29 cell line, isolated from a primary colorectal adenocarcinoma, is a widely utilized model of the intestinal epithelium. These cells display characteristic epithelial morphology and are notable for their constitutive mucin production, enabling studies of intestinal mucosal biology and colorectal cancer pathogenesis. As a well-characterized cancer cell line, HT29 cells harbor mutations typical of colorectal carcinogenesis, creating a physiologically relevant context for interrogating oncogenic signaling pathways. Their reproducible growth kinetics and amenability to standard transfection and culture protocols enhance experimental consistency in knockout applications.
GXYLT1 encodes a xylosyltransferase that catalyzes the addition of xylose to glucose residues on epidermal growth factor (EGF)-like repeats of Notch receptors, a critical post-translational modification in Notch maturation. This glycosylation step is essential for proper receptor folding, trafficking, and ligand-dependent activation, where GXYLT1 functions downstream of transcriptional regulation and interacts with POFUT1 within the glycosyltransferase complex that processes Notch extracellular domains. Through its enzymatic activity, GXYLT1 modulates the sensitivity of Notch receptors to ligands such as DLL4 and JAG1, thereby influencing the NICD-RBPJ-MAML1 transcriptional complex and the expression of downstream effectors like HES1, HEY1, and HEY2, ultimately governing cell fate decisions, proliferation, and differentiation.
In the HT29 cellular environment, ablation of GXYLT1 disrupts Notch receptor xylosylation, leading to altered ligand responsiveness and downstream signaling dynamics. Given the well-documented role of Notch signaling in intestinal stem cell maintenance, goblet cell differentiation, and colorectal tumorigenesis, this knockout model provides a valuable platform to delineate how glycosylation-dependent tuning of Notch activity influences epithelial cancer biology. The interaction between GXYLT1-mediated modification and HT29 mucin production further allows dissection of the link between Notch signaling and the secretory phenotype, aiding exploration of how aberrant glycosylation contributes to oncogenic progression and therapeutic resistance in colorectal adenocarcinoma.
These polyclonal knockout cells support a broad range of experimental approaches, including Western blotting for NOTCH1 and HES1 protein levels, RT-qPCR for Notch target gene expression, and luciferase-based Notch reporter assays to quantitatively assess pathway activity. Immunofluorescence and flow cytometry enable examination of Notch receptor surface localization, while co-immunoprecipitation facilitates analysis of GXYLT1-Notch interactions. Glycosylation profiling via mass spectrometry permits detailed mapping of altered xylosylation patterns. Collectively, these applications underpin investigations into Notch signaling mechanisms, colorectal cancer progression, glycobiology, and drug target identification. For further details or technical assistance, please contact Ascent Research.
